Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments
I'm PortAI, I can summarize articles.
Michael Okunewitch from Maxim Group maintains a Buy rating on Longeveron with a price target of $4.00, citing progress in clinical trials and potential catalysts. The ELPIS II trial for hypoplastic left heart syndrome has completed enrollment, with pivotal results expected in Q3 2026. A positive outcome could lead to approval filing. Favorable regulatory conditions and strategic adjustments, including cost optimization and funding efforts, enhance the outlook. Roth MKM also reiterated a Buy rating with a $3.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments